Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has added a new report analysing stem call-based therapeutic delivery.
“Stem Cell-Based Therapeutic Delivery: Challenges & Opportunities”
The 180 page report shows that stem cell-derived therapeutics are on the brink of a new era, with a handful of therapies expected on the market within the next two or three years. Big pharma and biotech companies such as Pfizer and Genyzme have recently invested large sums in this exciting and fast-moving area, further demonstrating its growing maturity.
Authors of the report note that stem cell therapies are already offered at various locations across the globe, including China and Thailand, despite a lack of robust, randomised clinical trials demonstrating their safety and efficacy. The fact that stem cell therapies are available in these locations and that patients' travel across the globe to receive them illustrates the high unmet medical need associated with some of the targets being investigated. Clinical evidence from high quality clinical trials is now imperative in order to protect these vulnerable patient populations.
However, the challenges facing companies developing stem cell-derived therapies are high and range from ethical discussions surrounding the use of human embryonic stem cells (hESCs) to difficulties associated with manufacture of cell-based products at scale and proving that products lack the potential to cause an immune response or cancer in a recipient. Nevertheless a growing pool of companies is investing heavily to bring this rapidly moving science to the clinic.
“Stem Cell-Based Therapeutic Delivery: Challenges & Opportunities”
Piribo product ID: PAV00008
